CTOs on the Move

Relypsa

www.relypsa.com

 
Relypsa is a biopharmaceutical company leading the discovery, development and commercialization of polymer-based medicines to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patient lives or even be life-threatening. Relypsa was founded in October 2007 and is headquartered in Redwood City, Calif. In 2015, we received FDA approval for our first medicine, which was developed based on our polymer technology platform for the treatment of hyperkalemia. In September 2016, Relypsa became a Vifor Pharma company. Today, we have more than 400 employees united by a passion for improving people’s lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.relypsa.com
  • 100 Cardinal Way
    Redwood City, CA USA 94063
  • Phone: 650.421.9500

Executives

Name Title Contact Details
Bill Yates
 Chief Information Officer and Vice President Profile

Similar Companies

AltPep

AltPep Corporation is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world`s most intractable diseases: amyloid diseases. We are currently focusing on CNS disorders, in particular Alzheimer`s Disease (AD). We target and seek to neutralize the early toxic oligomers behind these amyloid diseases, which in the case of AD are due to aggregation of the Amyloid-beta peptide (Abeta).

Girindus America

Girindus America is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ASD BioSystems Inc

ASD BioSystems Inc is a Gretna, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.